Parasite Viability as a Superior Measure of Antimalarial Drug Activity in Humans.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
15 06 2021
Historique:
received: 23 07 2020
accepted: 22 10 2020
pubmed: 30 10 2020
medline: 15 2 2022
entrez: 29 10 2020
Statut: ppublish

Résumé

Artemisinin derivatives are the leading class of antimalarial drugs due to their rapid onset of action and rapid clearance of circulating parasites. The parasite clearance half-life measures the rate of loss of parasites from blood after treatment, and this is currently used to assess antimalarial activity of novel agents and to monitor resistance. However, a number of recent studies have challenged the use of parasite clearance to measure drug activity, arguing that many circulating parasites may be nonviable. Plasmodium falciparum-infected subjects (n = 10) in a malaria volunteer infection study were administered a single dose of artesunate (2 mg/kg). Circulating parasite concentration was assessed by means of quantitative polymerase chain reaction (qPCR). Parasite viability after artesunate administration was estimated by mathematical modeling of the ex vivo growth of parasites collected from subjects. We showed that in artemisinin-sensitive infection, viable parasites declined to <0.1% of baseline within 8 hours after artesunate administration, while the total number of circulating parasites measured with quantitative polymerase chain reaction remained unchanged. In artemisinin-resistant infections over the same interval, viable parasites declined to 51.4% (standard error of the mean, 4.6%) of baseline. These results demonstrate that in vivo drug activity of artesunate is faster than is indicated by the parasite clearance half-life.

Sections du résumé

BACKGROUND
Artemisinin derivatives are the leading class of antimalarial drugs due to their rapid onset of action and rapid clearance of circulating parasites. The parasite clearance half-life measures the rate of loss of parasites from blood after treatment, and this is currently used to assess antimalarial activity of novel agents and to monitor resistance. However, a number of recent studies have challenged the use of parasite clearance to measure drug activity, arguing that many circulating parasites may be nonviable.
METHODS
Plasmodium falciparum-infected subjects (n = 10) in a malaria volunteer infection study were administered a single dose of artesunate (2 mg/kg). Circulating parasite concentration was assessed by means of quantitative polymerase chain reaction (qPCR). Parasite viability after artesunate administration was estimated by mathematical modeling of the ex vivo growth of parasites collected from subjects.
RESULTS
We showed that in artemisinin-sensitive infection, viable parasites declined to <0.1% of baseline within 8 hours after artesunate administration, while the total number of circulating parasites measured with quantitative polymerase chain reaction remained unchanged. In artemisinin-resistant infections over the same interval, viable parasites declined to 51.4% (standard error of the mean, 4.6%) of baseline.
CONCLUSIONS
These results demonstrate that in vivo drug activity of artesunate is faster than is indicated by the parasite clearance half-life.

Identifiants

pubmed: 33119072
pii: 5943003
doi: 10.1093/infdis/jiaa678
doi:

Substances chimiques

Antimalarials 0
Artemisinins 0
Artesunate 60W3249T9M

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2154-2163

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Auteurs

Maria Rebelo (M)

QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Rebecca Pawliw (R)

QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Jeremy Gower (J)

QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Lachlan Webb (L)

QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Hayley Mitchell (H)

QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Zuleima Pava (Z)

QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Rebecca E Watts (RE)

QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Miles P Davenport (MP)

Kirby Institute, University of New South Wales (Sydney), Sydney, New South Wales, Australia.

James S McCarthy (JS)

QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

David S Khoury (DS)

Kirby Institute, University of New South Wales (Sydney), Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH